Clinical Trial Update: A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors [Phase 1]

View source ↗

Summary

This Phase 1 pharmacokinetic study evaluated how coadministration of rabeprazole and rifampin affects dabrafenib exposure in patients with BRAF V600 mutation–po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Dabrafenib (Dabrafenib)
• RIFAMPIN (RIFAMPIN)
• Rabeprazole (rabeprazole)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cancer | Phase 1 | Status: COMPLETED